cultured supernatant was obtained after the cells (2.5 × 10 4 ) were cultured for 5 days at 37˚C in RPMI 1640 medium (Nissui Co.) supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin and also with 3 × 10 -8 mol/L Na2SeO3, 3 × 10 -10 mol/L MnCl2, 3 × 10 -9 mol/L (NH4)6Mo7O24, 1 × 10 -8 mol/L NH4VO3, 1 × 10 -7 mol/L FeSO4, 3 × 10 -3 mol/L oleic acid, 3 × 10 -3 mol/L linoleic acid, 5 mmol/L 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES). 18 
Materials and reagents
7-Hydroxycoumarin-3-carboxylic acid (CM) was purchased from Molecular Probes Inc. (Leiden, The Netherlands) and 2-aminopyridyl-β-alanine (PA) from Wako (Osaka, Japan). Galβ1-3GlcNAc, Galβ1-4GlcNAc, cytidine 5′-monophospho-α-D-N-acetylneuraminic acid (CMP-Neu5Ac), uridine 5′-diphospho-β-D-galactose (UDP-Gal), guanosine 5′-diphospho-α-L-fucose (GDP-Fuc) were obtained from Sigma Chemical Co.
(St. Louis, MO). Lewis y tetrasaccharide, Fucα1-2Galβ1-4(Fucα1-3)GlcNAc, was purchased from Calbiochem Co. (La Jolla, CA).
Anti-human transferrin, α1-antitrypsin, α2-HS glycoprotein and β2-glycoprotein goat anti-sera were purchased from Chemicon International Inc. (Temecula, CA). Anti-sialyl Lewis X mouse monoclonal IgM (CSLEX-1) (American Type Culture Collection, Manassas, VA), control mouse IgM (Chemicon) and horseradish peroxidase-conjugated goat anti-mouse IgM (Jackson ImmunoResearch Lab., West Grove, PA) were used for immunoblotting. Protein G-Sepharose 4 fast-flow column (5 mL), HiTrap-NHS column (1 mL) and Immobiline Dry-Strip (130 mm, pH 3 -10, linear) were purchased from Amersham Biosciences (Piscataway, NJ). Wakosil 5C4 (4.6 i.d. × 150 mm, 5 µm of a particle size) and Wakopak Handy-ODS columns (4.6 i.d. × 150 mm, 5 µm of a particle size) were obtained from Wako. N-Glycanase was obtained from Oxford GlycoSciences (Oxford, UK) and α2-3 sialyltransferase (rat liver) from Roche Diagnostics (Basel, Switzerland). ZipTips C18 resin (15 µm, 0.6 µL packed volume) was obtained from Millipore Japan (Tokyo, Japan). Glycan preparation kit (cellulose cartridge, 1 mL packed volume), α1-2 fucosidase (Arthrobacter sp.) and α1-3/4 fucosidase (Streptomyces sp.142) were purchased from TaKaRa (Tokyo, Japan). α2-3/6 Neuraminidase (Streptococcus 6646K) and β-galactosidase (Streptococcus sp.) were obtained from Seikagaku Co. (Tokyo, Japan).
α-Cyano-4-hydroxycinnamic acid (CHCA), 2,5-dihydroxybenzoic acid (DHB) and adrenocorticotropic hormone (ACTH) 11-39 clip were purchased from Sigma Aldrich Japan (Tokyo, Japan). All other reagents and chemicals used were of analytical grade.
Two-dimensional polyacrylamide gel electrophoresis
The HepG2 and HuH-7 cultured supernatant (about 1 L) was ultrafiltrated using ultrafilter UP-20 (cut off 20 kDa, Advantec, Tokyo, Japan). The concentrated supernatant (5 mg/ml) was cleaned up by 2D clean-up kit (Amersham Biosciences), and then solubilized in 6 mol/L urea, 2% (w/v) CHAPS, 40 mmol/L dithiothreitol (DTT), and 0.05% (v/v) carrier ampholytes (IPG buffer, pH 3 -10 linear, Amersham Biosciences). The proteins were separated by isoelectric focusing electrophoresis (IEF) in the first dimension and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) in the second dimension. The samples used were 50 µg of protein for silverstaining and 100 µg of protein for immunoblotting. Protein contents were determined by an advanced protein assay kit (Cytoskeleton, Denver, CO) using bovine serum albumin as a standard.
The strips (130 mm, pH 3 -10, linear) were allowed to rehydrate using rehydration buffer at 20˚C overnight and then transferred to IPGphor cup-loading strip holders and covered with paraffin oil. The proteins (50 µg or 100 µg in 50 µL) were focused for 1 min at 500 V followed by a linear gradient of voltage from 500 to 4000 V for 1.5 h and a step gradient from 4000 to 8000 V for 3 h using IPGphor (Amersham Biosciences). The isoelectric focusing was then completed at a constant voltage of 8000 V until 40000 Vh. Subsequently, the strips were equilibrated first for 10 min in 50 mmol/L Tris-HCl (pH 6.8), 6 mol/L urea, 30% (v/v) glycerol, 2% (w/v) SDS, and 40 mmol/L DTT and then for 10 min in the same buffer without DTT but with 2.5% (w/v) iodoacetamide and a trace of bromophenol blue. In the second dimension, SDS-PAGE according to Laemmli 19 was carried out in an 8% acrylamide slab gel (150 × 150 mm) using a Model NA-1120 electrophoresis system (Nihon Eido Co., Tokyo, Japan). Proteins were detected by Silver Stain II kit Wako (Wako) and Negative Gel Stain MS kit (Wako) was used in protein detection for PMF analysis.
Western blotting
After SDS-PAGE, proteins were electronically transferred to nitrocellulose membrane (Schleicher & Schuell, Dassel, Deutschland) for 1 h at 2 mA/cm 2 . After blocking the membrane with 1% (w/v) bovine serum albumin in PBS at 4˚C overnight, the blot was incubated with CSLEX-1 at a 1:100 dilution in PBS containing 0.01% (v/v) Tween-20 (PBS-T) for 1 h. The membrane was washed with PBS-T three times and incubated with horseradish peroxidase-conjugated goat antimouse IgM at a 1:1000 dilution. These spots were visualized with Konica Immunostaining HRP-1000 (Seikagaku Co.).
Peptide mass fingerprinting
The in gel digestion was performed using a sequencing grade of modified trypsin (Roche Diagnostics) as described in literature. 20 After washing the gel piece with distilled water and acetonitrile, the gels were dried by a centrifugal concentrator under vacuum. The dried gel piece was rehydrated by adding 10 µL of 100 mmol/L Tris-HCl (pH 8.0) containing 10 ng/µL of trypsin and incubated at 4˚C for 45 min. After rehydration, the supernatant was removed and 10 µL of 100 mmol/L Tris-HCl (pH 8.0) was added to the gel piece followed by incubation at 37˚C overnight. Peptides were extracted by adding 20 µL of 60% (v/v) acetonitrile containing 5% (v/v) formic acid. The extraction was repeated three times and completed by adding 20 µL of the same reagent. The extracted solutions were pooled and evaporated to dryness in a SpeedVac vacuum centrifugal concentrator. Samples were reconstituted in 10 µL of 0.1% (v/v) trifluoroacetic acid (TFA) and treated with ZipTips C18 resin according to the manufacturer's instructions.
Purification of glycoproteins from HepG2 cultured supernatant
Anti-human transferrin, α1-antitrypsin, α2-HS glycoprotein and β2-glycoprotein antibodies purified on Protein G-Sepharose 4 fast flow columns (1 mL, packed volume) were coupled to a HiTrap-NHS column (1 mL, packed volume) according to manufacturer's instructions. The concentrated HepG2 cultured supernatant was applied on the affinity columns. After the columns were washed with 20 mmol/L phosphate buffer (pH 7.0), each glycoprotein was eluted with 100 mmol/L glycine buffer (pH 2.7). The eluted fraction (5 mL) was concentrated to 200 µL with centrifugal filter and injected onto a Wakosil 5C4 column. The glycoprotein was eluted with two solvent systems of solutions A and B at a flow rate of 1 mL/min using an increasing gradient of B in A, 1 to 100% (v/v) of B for 30 min.
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Solution A was composed of 20 mmol/L ammonium acetate (pH 4.0) and solution B was 50% (v/v) acetonitrile in A. The eluate was monitored at 280 nm. The glycoprotein fractions (1 -2 mL) were concentrated to 100 µL using a centrifugal concentrator.
Release and purification of N-glycans from glycoproteins
To the protein solution (100 µL, 250 µg/ml), 1 µL of 10% (w/v) SDS, 1 µL of 2-mercaptoethanol and 10 µL of 1 mol/L 2-(morpholino)ethanesulfonic acid (MES) buffer (pH 7.5) were added; then protein was denatured by boiling for 3 min. After addition of 10 µL of 10% (v/v) Nonidet P-40 and 1 µL of Nglycanase (1 U/mL), the solution was incubated at 37˚C overnight.
The N-glycan solution was mixed with an equal volume of ethanol, and then the mixture was centrifuged at 16000g for 10 min. The supernatant was added to 4 volumes of 1-butanol, and applied on a cellulose cartridge (1 mL, packed volume). After the material was washed with 5 mL of 1-butanol/ethanol/distilled water (4/1/1), N-glycan was eluted with 1 mL of 50% (v/v) ethanol. The eluate was concentrated to 10 µL using a centrifugal concentrator.
MALDI-TOFMS for peptide mixtures and protein identification
Peptide mixtures were analyzed by MALDI-TOFMS using a Model Voyager-DE STR (Applied Biosystems, Foster, CA). Peptide mixtures eluted from ZipTips C18 resin with 5 µL of 75% (v/v) acetonitrile in 0.1% (v/v) TFA were mixed with an equal volume of matrix solution consisting of 10 mg/mL CHCA in 50% (v/v) acetonitrile containing 0.1% TFA. A 0.5-µL volume of admixture was spotted on a target, dried at room temperature and applied on Voyager-DE STR. The mass spectrometer was operated in a positive reflector mode. An accelerating voltage of 25 kV, grid voltage of 75% and nitrogen laser at 337 nm were used and 256 laser shots were fired to obtain mass spectra. Molecular ions [MH + ] of ACTH 11-39 clip (monoisotopic mass: 2465.1989) and CHCA dimer (monoisotopic mass: 379.0930) were used as external calibrators. Processing was used with the Applied Biosystems "Grams" software. Database searches were based on the MS-Fit (the World Wide Web at http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm) using all Homo sapiens proteins in the NCBI database allowing a mass accuracy of 200 ppm for the peptide masses.
MALDI-TOFMS for sialic acid-containing N-glycans
A part of sialic acid-containing N-glycan was dissolved in 2 µL of dimethylsulfoxide (DMSO) and 2 µL of methyl iodide and the mixture was allowed to stand for 2 h at room temperature. After addition of 2 µL of DMSO and dryness in vacuo, 5 µL of matrix solution consisting of 10 mg/mL DHB in 50% (v/v) ethanol was added. An admixture (0.5 µL) was applied on Voyager DE-STR. The mass spectrometer was operated in a positive linear mode. An accelerating voltage of 20 kV, grid voltage of 95% and nitrogen laser at 337 nm were used for methyl esters of glycans and 256 laser shots were fired to obtain mass spectra.
MALDI-TOFMS for exoglycosidase-treated N-glycans
The purified N-glycans were dissolved in 10 µL of distilled water and incubated with 5 µL of α2-3/6 neuraminidase from Streptococcus 6646K (1 U/mL) dialyzed against 50 mmol/L ammonium acetate (pH 6.5) at 37˚C overnight. The asialo Nglycans were then treated with 5 µL of α1-3/4 fucosidase from Streptomyces sp.142 (1 mU/mL) at 37˚C overnight. The asialoafucosyl N-glycans were then digested with 5 µL of β-galactosidase from Streptococcus 6646K (1 mU/mL) dialyzed against 50 mmol/L ammonium acetate (pH 6.5) at 37˚C overnight. The exoglycosidase-treated N-glycans were applied on a cellulose cartridge and then eluted with 50% (v/v) ethanol. The eluate was dried by a centrifugal concentrator under vacuum.
The sample was dissolved in 8 µL of distilled water and an equal volume of matrix solution (10 mg/mL DHB) was added. An admixture (0.5 µL) was analyzed by MALDI-TOFMS, using a reflector mode, an accelerating voltage of 20 kV, a grid voltage of 65% and nitrogen laser at 337 nm; positive ions were detected.
Glycosyltransferase assay
Galactosyltransferase (GalT) and sialyltransferase (ST) activities were determined using fluorescence-tagged substrates and high performance liquid chromatography (HPLC), as described in literature. 21 We further developed assay methods for α1-2 and α1-3/4-fucosyltransferase (FT) activities. The fucosylated products for FT assay were prepared from Lewis y tetrasaccharide. This Lewis y tetrasaccharide was aminated and coupled with PA; PA-tagged compound was purified by HPLC in the same condition in literature. 21 Galβ1-4(Fucα1-3)GlcNAc-PA and Fucα1-2Galβ1-4GlcNAc-PA were obtained from Lewis y tetrasaccharide-PA by α1,2-fucosidase and α1,3/4-fucosidase treatment.
The FT assay mixture was composed of 100 mmol/L HEPES buffer (pH 7.5), 30 mmol/L MnCl2, 1.0 mmol/L GDP-Fuc, 1.0 mmol/L Galβ1-4GlcNAc-PA, Galβ1-3GlcNAc-PA or Neu5Acα2-3Galβ1-4GlcNAc-CM and 100 µg protein of cell homogenates in a total volume of 20 µL. The mixture was incubated for 8 h at 37˚C. Neu5Acα2-3Galβ1-4GlcNAc-CM was enzymatically prepared from Galβ1-4GlcNAc-CM using the reaction of α2-3 sialyltransferase (rat liver) and CMPNeu5Ac.
The FT reaction mixture diluted with 100 µL of distilled water was denatured by boiling for 3 min and centrifuged at 16000g for 3 min. An aliquot was injected onto Wakopak Handy-ODS (55˚C) and the enzymatic products were separated from excess substrates at a flow rate of 1.0 mL/min using mobile phases of 2% and 5% (v/v) acetonitrile in 10 mmol/L ammonium acetate for Galβ1-3/4GlcNAc-PA and Neu5Acα2-3Galβ1-4GlcNAc-CM as substrates, respectively. The eluent was monitored by a Model FS-8020 fluorescence detector (Tosoh Co., Tokyo, Japan) at Ex 308 nm and Em 370 nm for Galβ1-3/4GlcNAc-PA and Ex 330 nm and Em 450 nm for Neu5Acα2-3Galβ1-4GlcNAc-CM. The peak areas of the enzymatic products were calculated by a Model LC-8020 Multi Station (Tosoh Co.).
Results

Analysis of sialyl Lewis X expressing glycoproteins secreted by HepG2 cells
The concentrated supernatants from HepG2 and HuH-7 cells were cleaned up and separated by IEF in the first dimension and SDS-8% PAGE in the second dimension. The proteins were visualized by silver staining and immunoblotted with CSLEX-1 (Fig. 1) .
Proteins in the supernatants from HepG2 and HuH-7 cells were separated to about 250 spots (Figs. 1A and B) . CSLEX-1 bound to 4 kinds of proteins in HepG2 supernatant (Fig. 1C) : 80 kDa (pI 6 -8), 60 kDa (pI 4.5 -5), 55 kDa (pI 4 -4.5) and 58 kDa (pI 6 -8), although slight differences of electrophorograms between silver staining (Fig. 1A) and immunoblotting (Fig. 1C) would be caused by the different staining procedures. On the other hand, no proteins in HuH-7 supernatant was detected by CSLEX-1 immunoblotting (Fig. 1D) . Comparing the CSLEX-1 binding patterns with the reference pattern of HepG2 cell supernatant reported in literature, 22 one can match the relative positions of three species with transferrin, α1-antitrypsin and α2-HS-glycoprotein. To confirm these proteins and identify another one, we analyzed using MALDI-TOFMS in combination with in gel digestion based on PMF. Searching the Homo sapiens proteins in NCBI database, mass signals matched/obtained were 19/26, 7/9, 4/6, and 5/10 for transferrin, α1-antitrypsin, α2-HS-glycoprotein, and β2-glycoprotein, respectively.
To estimate SLEX-expressing glycoproteins, these glycoproteins were purified by antibodies-immobilized affinity columns and HPLC.
These purified glycoproteins were immunoblotted with CSLEX-1 (data not shown).
N-Glycan analysis of transferrin, α1-antitrypsin, α2-HSglycoprotein, and β2-glycoprotein
N-Glycans on each glycoprotein released with N-glycanase and purified on cellulose cartridge were analyzed using MALDI-TOFMS in combination with exoglycosidase digestion. Typical mass spectra for N-glycans on transferrin in HepG2 supernatant are shown in Fig. 2 and their proposed glycan compositions are listed in Table 1. MALDI-TOF mass spectra of sialic acid-containing N-glycans from transferrin after esterification with methyl iodide were detected as positive ions [M+Na] + using a linear mode ( Fig.  2A) . By treatment with α2-3/6 neuraminidase, N-glycanderived signals were simplified to those corresponding to bi-, tri-and tetra-antennary complex N-glycans with or without Fuc by MALDI-TOFMS using a reflector mode (Fig. 2B) . To determine the linkage of glycan, desialylated glycans were treated with α1-3/4-fucosidase and β-galactosidase and applied to MALDI-TOFMS analysis. The signals that corresponded to α1-3/4 fucosylated glycans were reduced by one to four Fuc mass units and converted to signals at m/z 1664.0, 2029.2 and 2394.4 (Fig. 2C) . The results indicated that Fuc in N-glycans on each glycoprotein was determined to be α1-3/4 linked but not α1-2 and α1-6 linked. To estimate the signals at m/z 1664.0, 2029.2 and 2394.4, asialo-afucosyl N-glycans were digested with β-galactosidase; these signals were converted to those at m/z 1339.6, 1542.8 and 1745.9, respectively (Fig. 2D) . Since reduced mass units of 324.4, 487.2 and 648.5 corresponded to two, three and four hexose mass units, respectively, the results indicated that N-glycans were constructed with bi-, tri-and tetra-antennary N-glycans and did not contain polylactosamine.
At the present time, quantitative analysis for sialylated glycans has not been achieved. We determined the desialylated N-glycans in these glycoproteins.
Quantitative MALDI- TOFMS for neutral N-glycans will be described elsewhere. The results are shown in Table 2 . Although transferrin from HuH-7 supernatant was not immunoblotted with CSLEX-1, half of the N-glycans were fucosylated but most of them were monofucosylated. On the other hand, N-glycans of transferrin from HepG2 supernatant increased in fucosylated N-glycans especially in poly-fucosylated N-glycans. Furthermore, an increase in high-branched tetra-antennary N-glycans were obtained in transferrin from HepG2 supernatant comparing with HuH-7. Increased contents of poly-fucosylated and highbranched N-glycans were also obtained in three other glycoproteins from HepG2 supernatant.
Glycosyltransferase activities in HepG2 and HuH-7 cells
We assayed the glycosyltransferase activities in HepG2 and HuH-7 cells using CM or PA-tagged sugars as the fluorescence substrates; the enzymatic products were determined by HPLC. Furthermore, this method was able to separate stereoisomers of Galβ1-4(Fucα1-3) GlcNAc-PA and Fucα1-2Galβ1-4GlcNAc-PA, as shown in Fig. 3 . The FT reaction products in HuH-7 and HepG2 cell lysate were eluted at the same retention times as peak 1 and 5 of standards. The FT products purified by HPLC were confirmed by treatment with α1-2 and α1-3/4 fucosidases. The results are shown in Table 3 . α1-3 FT activities in HepG2 cells for Galβ1-4GlcNAc-PA and Neu5Acα2-3Galβ1-4GlcNAc-CM as substrates were about 10-and 40-folds higher than HuH-7 cells, respectively. α1-4 FT activities for type I (Galβ1-3GlcNAc-PA) were not detected in either HepG2 or HuH-7 cells.
Discussion
We comparatively studied SLEX-expressing glycoproteins secreted from human hepatocellular carcinoma cell lines HepG2 and HuH-7. Proteins in HepG2 and HuH-7 cells supernatants were separated by 2D-PAGE and immunoblotted with anti-SLEX (CSLEX-1). HepG2 cells indicated high expression of SLEX antigen on secreted proteins by comparison with HuH-7 cells.
SLEX-expressing glycoproteins were identified as transferrin, α1-antitrypsin, α2-HS-glycoprotein, and β2-glycoprotein using MALDI-TOFMS in combination with in gel digestion and PMF method.
Transferrin, α1-antitrypsin, α2-HS-glycoprotein, and β2-glycoprotein have several glycosylation sites in a molecule, i.e., two N-and one O-in transferrin (P02787, accession number in SWISS-PROT), three N-in α1-antitrypsin (P01009), two N-and three O-in α2-HS glycoprotein (P02765), and four N-and one O-glycosylation sites in β2-glycoprotein (P02749). N-Glycans of these glycoproteins in normal sera have been reported. NGlycans were mainly composed of bi-antennary complex-type with few tri-and tetra-antennary complex-types, including minor bi-antennary N-glycans with α1-6 linked Fuc to innermost GlcNAc or bisecting β1-4 linked GlcNAc to trimannosyl core, i.e., transferrin, 23 α1-antitrypsin, 24 α2-HSglycoprotein, 25 and β2-glycoprotein. 26 Alteration of glycans in sera of patients with inflammation and hepatocellular carcinoma has been explained in many reports.
7,23,27,28 Induced SLEX expression was reported in α1- acid glycoprotein, α1-antitrypsin and haptoglobin in sera of inflammatory patients 29 and also in α1-acid glycoprotein secreted by IL-1β-stimulated HuH-7 cells. 30 Alteration of Nglycans of transferrin in sera of patients with hepatocellular carcinoma was also reported including increases in highbranched N-glycans, α1-3 and α1-6 fucosylation, and appearance of bisecting GlcNAc. 31 Increased SLEX levels were also reported in sera of patient with hepatocellular carcinoma. 32 Furthermore, the presence of α1-3 fucosylated tri-, tetra-and penta-antennary N-glycans were reported in transferrin from HepG2 supernatant. 33 These results indicated that expression of glycosyltransferases and synthesis of glycans were disturbed in inflammation and malignant transformation. Several mass spectrometric approaches for analysis of glycan structures have been reported. [11] [12] [13] [14] [15] [16] [17] 34, 35 We analyzed N-glycans of these glycoproteins using MALDI-TOFMS in combination with exoglycosidase digestion. The results indicated that increases in α1-3 fucosylated, poly-fucosylated, and highbranched N-glycans occurred not only on transferrin but also on α1-antitrypsin, α2-HS-glycoprotein, and β2-glycoprotein.
Although we could not detect SLEX expression in other glycoproteins secreted by HepG2 cells at low levels, such as α1-acid glycoprotein and haptoglobin, similar alterations of Nglycans would commonly occur on other glycoproteins.
To clarify SLEX expression in HepG2 cells, glycosyltransferase activities in HepG2 and HuH-7 cells were determined using fluorescence-tagged acceptor substrates and HPLC. α1-3 FT activities in HepG2 cells for Galβ1-4GlcNAc-0PA and Neu5Acα2-3Galβ1-4GlcNAc-CM as substrates were determined about 10-and 40-folds higher than HuH-7 cells, respectively. The results indicated that α1-3 fucosylation on these glycoproteins in HepG2 cells would be mediated by the reaction of FT VI. 36 Expression of SLEX on glycoproteins secreted into circulating blood is induced during inflammation, rheumatoid arthritis and malignant transformation. 7, 37 SLEX expressing glycoproteins are speculated to influence the E-and P-selectin-mediated influx of leukocytes into inflamed areas 5, 38 and to modulate activated natural killer cells. 39 Proteo-glycomics analysis using MALDI-TOFMS is a useful and informative approach to elucidate pathophysiological functions of altered glycosylation on glycoproteins.
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